{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"27.0","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"CR rate is defined as percentage of participants who achieved best response of CR according to IMWG response criteria. CR is defined as per IMWG criteria as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and \\<5% PCs in bone marrow. No evidence of initial monoclonal protein isotype(s) on immunofixation of the serum and urine.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants aged 18 years or older, with multiple myeloma received the lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion and fludarabine 30 mg/m\\^2 IV infusion daily, for 3 days \\[Day -7 to Day -5\\]). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants received IV infusion of cilta-cel OOS at a total targeted dose of 0.75\\*10\\^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg (dose range 0.5\\*10\\^6 CAR-positive viable T cells/kg to 1.0\\*10\\^6 CAR-positive viable T cells/kg) based on participant's body weight at apheresis or per exceptional release criteria determined alternative dose.","id":"OG000","title":"Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS)"}],"paramType":"NUMBER","populationDescription":"The all treated analysis set included all participants who received study intervention (cilta-cel OOS).","reportingStatus":"POSTED","timeFrame":"From Day 1 (post infusion) up to 18.6 months","title":"Complete Response (CR) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}